CDC Updates Respiratory Syncytial Virus (RSV) Webpages

CDC continues to encourage health care providers to administer nirsevimab to protect infants against severe RSV and not save doses for later in the season as more nirsevimab is expected in early 2024. On January 3, the following CDC webpages were updated to emphasize immediate administration of nirsevimab to eligible infants:

For Healthcare Professionals: RSV (Respiratory Syncytial Virus)
Healthcare Providers: RSV Immunization for Children 19 Months and Younger
Frequently Asked Questions About RSV Vaccine for Children 19 Months and Younger
Preventing RSV (Respiratory Syncytial Virus)
RSV in Infants and Young Children
Preparing Patients for 2023 Virus Season